The mineralocorticoid receptor (MR) has been identified as an important therapeutic target for modifying disease severity in Duchenne muscular dystrophy (Duboc et al., 2005; Rafael-Fortney et al., 2011, 2016; Sayer and Bhat, 2014; Chadwick et al., 2015, 2017a; Lowe et al., 2016; Raman et al., 2017; Hauck et al., 2019). Here, NR3C2 is linked to Duchenne muscular dystrophy.